Frederic Ors

Consortium Québécois sur la Découverte du Médicament (CQDM) is a not-for-profit biopharmaceutical research consortium based in Montréal, Canada. CQDM's mission is to support and facilitate multi-stakeholder collaborative R&D aimed at accelerating the translation of innovative technologies into solutions that address unmet medical needs, while generating significant benefits for the Quebec and Canadian economy. CQDM funds the development of innovative tools and technologies that accelerate the discovery and development of safer and more effective drugs. The company's Quantum Leap pharma-led funding program for drug discovery research helps SMEs or Canadian universities achieve innovative translational biopharmaceutical research projects. CQDM's SynergiQC-International program is designed to promote university-based industrial research in the biopharmaceutical field with collaborators outside, that will generate economic benefits. The non-profit company was founded by Max Fehlmann.

Consortium Québécois sur la Découverte du Médicament (CQDM) is a not-for-profit biopharmaceutical research consortium based in Montréal, Canada. CQDM's mission is to support and facilitate multi-stakeholder collaborative R&D aimed at accelerating the translation of innovative technologies into solutions that address unmet medical needs, while generating significant benefits for the Quebec and Canadian economy. CQDM funds the development of innovative tools and technologies that accelerate the discovery and development of safer and more effective drugs. The company's Quantum Leap pharma-led funding program for drug discovery research helps SMEs or Canadian universities achieve innovative translational biopharmaceutical research projects. CQDM's SynergiQC-International program is designed to promote university-based industrial research in the biopharmaceutical field with collaborators outside, that will generate economic benefits. The non-profit company was founded by Max Fehlmann.